Kerala Ayurveda

Kochi, India Founded: 1945 • Age: 81 yrs Listed
Chain of complementary and alternative therapy hospitals
Request Access
Report Incorrect Data
Page last updated

About Kerala Ayurveda

Kerala Ayurveda is a publicly listed company based in Kochi (India) founded in 1945. Chain of complementary and alternative therapy hospitals. The company has 367 employees. Its website keralaayurveda.biz draws about 32 thousand monthly visits. Its Indian entity Kerala Ayurveda Limited reported revenue of ₹145 Cr. Kerala Ayurveda offers products and services including Myaxyl Oil, Triphala Tablets, Neelibringadi Keram, and Brahmi Pearls Capsules. Its focus areas include Hospital Chains and Ayurveda. Its competitors include AyurVAID Hospitals, AVN Arogya and Sreedhareeyam; 1 of its 3 listed competitors has raised funding.

Company details

Kerala Ayurveda, established in 1945, excels in providing healthcare solutions, hospital chains, complementary and alternative therapy hospitals, and ayurveda. Chain of complementary and alternative therapy hospitals. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.

  • Headquarters Kochi, India
  • Employees 367
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Alternative and Natural Medicine
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website keralaayurveda.biz
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Kerala Ayurveda Limited
Operational Areas
Healthcare → Hospitals & Clinical Care
Key Metrics
  • Market Cap
    ₹208 Cr

    KERALAYUR · BSE

  • Share Price
    ₹149.85

    -1.48% today

  • Revenue
    ₹131 Cr

    FY 2025-26 · +4.4% YoY

  • EBITDA
    −₹17.75 Cr

    Margin -13.5%

  • Net Profit
    −₹16.56 Cr

    FY 2025-26 · -18.7% YoY

  • Employee Count
    367

Products & Services of Kerala Ayurveda

Kerala Ayurveda offers a comprehensive portfolio of products and services, including Myaxyl Oil, Triphala Tablets, Neelibringadi Keram, and Brahmi Pearls Capsules.

Myaxyl Oil
Pain Relief

Provides relief from joint and muscle pain naturally

Triphala Tablets
Gut Health

Supports digestion and overall gut wellness effectively

Neelibringadi Keram
Hair Care

Promotes hair growth and reduces dandruff issues

Brahmi Pearls Capsules
Brain Health

Enhances memory and reduces stress levels

Apps and channels of Kerala Ayurveda

its YouTube channel Kerala Ayurveda has 4.17K subscribers and 30 videos.

Kerala Ayurveda
YouTube 4.17K subscribers 30 videos Howto & Style
Open channel

Videos from Kerala Ayurveda

The most watched videos on Kerala Ayurveda's YouTube channel, Kerala Ayurveda (4.17K subscribers). Click a video to play it here.

Kerala Ayurveda Ltd. Corporate Video 2017
17.6K views
Bollywood Icon Shakti Kapoor's Transformational Journey at Ayurvedagram #ayurvedagram #shaktikapoor
5.7K views
Kerala Ayurveda’s Chyavanprash, prepared using the 5000-Yr old recipe taken from Ashtanga Hridayam
4.2K views
All about Ojas!
3.6K views

More on Kerala Ayurveda.

Board of directors of Kerala Ayurveda Limited (Kerala Ayurveda)

Kerala Ayurveda Limited is the primary company behind Kerala Ayurveda. The board of Kerala Ayurveda Limited currently have 8 directors; the longest-serving is Kunjupanicker Anilkumar, appointed in 2006. 29 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Kunjupanicker Anilkumar
DIN 00226353
Whole-time director28 Jun 200620 yrs 4 moKerala Ayurveda Limited
Ramesh Vangal
DIN 00064018
Director02 Sep 200620 yrs 2 moKerala Ayurveda Limited
Shilpa Kiran Gududur
DIN 09067581
Director15 Feb 20215 yrs 8 moKerala Ayurveda Limited
Rajesh Sharma
DIN 00811525
Director28 Jun 20224 yrs 4 moKerala Ayurveda Limited
Kshiti Ranjan Das
DIN 07212449
Director04 Oct 20242 yrs 1 moKerala Ayurveda Limited
Kodikannath Jayarajan
DIN 10798470
Director04 Oct 20242 yrs 1 moKerala Ayurveda Limited
Utkarsh Singh
DIN 09244896
Director19 Mar 20251 yr 7 moKerala Ayurveda Limited
Saif Khan
DIN 10780306
Director30 Jun 20251 yr 4 moKerala Ayurveda Limited

People of Kerala Ayurveda

7 people are tracked at Kerala Ayurveda (3 in leadership, 4 in team); the tracked headcount is 367.

NameRoleGroup
Vikranth Reddy
Head - Supply ServicesLeadership
Vivek Sunder
Chief Executive OfficerLeadership
Paul Varghese
Chief Commercial Officer (cco)Leadership
Ankit Sinha
Senior Product AnalystTeam
Varunraj Belgaonkar
Senior AnalystTeam
Rachel Mathai
Manager - Health ServicesTeam
Bhavya Burnwal
Marketing ManagerTeam
Premium access

Complete people profiles for Kerala Ayurveda

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Kerala Ayurveda

Kerala Ayurveda is a publicly listed company on the BSE with ticker symbol KERALAYUR in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date16 May 1995
  • Listed onBSE: 530163
  • Listed entityKerala Ayurveda Limited
  • Exchange sectorHealth technology
  • ISININE817B01025
  • Share price₹145.75 (-2.12% on the day) · 2026-10-14
  • Market capitalisation₹193 Cr
  • EPS (diluted, trailing year)₹-21.20
  • Volume (last session)19,892

Financials of Kerala Ayurveda

Exchange-reported figures of Kerala Ayurveda Limited, the listed company behind Kerala Ayurveda (BSE: KERALAYUR).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹131 Cr
+4.4% YoY
EBITDA
−₹17.75 Cr
-256.4% YoY
Profit After Tax
−₹16.56 Cr
-18.7% YoY
Net Worth
-
Total Assets
-
Total Debt
-

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue13112610893.4180.3562.0776.77
Revenue growth+4.4%+16.0%+15.9%+16.3%+29.5%-19.2%-
EBITDA(17.75)(4.98)8.532.619.520.837.36
EBITDA margin-13.5%-4.0%+7.9%+2.8%+11.9%+1.3%+9.6%
Profit before tax(16.37)(12.23)0.65(0.57)2.79(6.75)4.54
Net profit(16.56)(13.95)(0.57)(2.98)1.69(4.86)3.90
Net profit margin-12.6%-11.1%-0.5%-3.2%+2.1%-7.8%+5.1%
EPS (₹)(13.53)(11.60)(0.47)(0.85)2.24(4.59)3.69
Balance sheet
Total assets-89.2310385.2382.6890.7582.81
Net worth-9.4918.655.586.113.417.93
Total debt-70.6676.0672.4469.9476.6964.16
Cash & bank-3.3922.813.202.8718.566.37
Net working capital-1.2425.974.589.5019.9214.11
Cash flow
Cash from operations-4.83(0.96)9.86(0.50)7.434.99
Cash from investing-(14.77)(0.45)(7.22)(1.91)(1.44)(4.03)
Cash from financing-(9.48)19.83(2.32)(13.27)6.200.85
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue33.1934.7432.9634.8428.6131.3231.1330.41
Revenue growth (YoY)+16.0%+10.9%+5.9%+14.6%+4.2%---
Other income0.261.911.131.709.470.730.230.64
EBITDA(3.83)(7.10)(1.51)(4.95)(4.19)(10.14)(1.19)5.53
EBITDA margin-11.5%-20.4%-4.6%-14.2%-14.6%-32.4%-3.8%+18.2%
Depreciation1.871.691.150.991.651.920.721.98
Interest2.791.102.842.580.822.480.430.72
Profit before tax(8.23)(7.98)(4.37)(6.82)2.81(13.81)(2.11)3.47
Tax(0.15)(0.59)0.23(0.46)0.781.560.59(0.17)
Net profit(8.08)(7.39)(4.60)(6.36)2.03(15.37)(2.70)3.64
EPS (₹)(6.24)(5.83)(3.81)(7.23)1.89(12.78)(2.40)3.10
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue85.4877.9573.1463.3055.8043.2053.68
Revenue growth+9.7%+6.6%+15.6%+13.4%+29.2%-19.5%-
EBITDA(23.02)(12.60)3.807.787.720.213.09
EBITDA margin-26.9%-16.2%+5.2%+12.3%+13.8%+0.5%+5.8%
Profit before tax(15.96)(13.50)(0.16)2.391.22(6.58)1.20
Net profit(14.75)(13.80)0.060.480.87(4.95)0.86
Net profit margin-17.3%-17.7%+0.1%+0.8%+1.6%-11.5%+1.6%
EPS (₹)(12.21)(11.45)0.042.740.84(4.69)0.83
Balance sheet
Total assets-86.0310282.8077.2084.6181.04
Net worth-25.1232.7714.5411.2810.0514.67
Total debt-55.5663.5763.6361.3966.0257.80
Cash & bank-0.3616.491.730.131.071.90
Net working capital-37.4130.1810.088.8916.1715.72
Cash flow
Cash from operations-2.28(5.30)9.128.75(0.91)4.71
Cash from investing-(6.48)(0.54)(5.32)0.83(2.10)(3.93)
Cash from financing-(11.93)20.59(2.27)(10.52)2.180.29
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue22.5324.5722.0721.2917.5719.3519.3518.60
Revenue growth (YoY)+28.2%+27.0%+14.1%+14.5%+14.1%---
Other income1.284.700.982.2610.004.370.130.39
Total expenses27.6235.0524.1326.3322.9930.3418.9919.15
EBITDA(5.09)(10.48)(2.06)(5.04)(5.42)(10.99)0.36(0.55)
EBITDA margin-22.6%-42.7%-9.3%-23.7%-30.8%-56.8%+1.9%-3.0%
Depreciation1.411.240.580.551.231.460.280.22
Interest2.811.971.982.540.772.810.380.33
Profit before tax(8.03)(8.99)(3.64)(5.87)2.58(10.89)(0.17)(0.71)
Tax(0.36)(1.07)(0.18)(0.47)0.510.98(0.08)(0.17)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 13 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue33.1934.7432.9634.8428.6131.3231.1330.41
Revenue growth (YoY)+16.0%+10.9%+5.9%+14.6%+4.2%---
Other income0.261.911.131.709.470.730.230.64
EBITDA(3.83)(7.10)(1.51)(4.95)(4.19)(10.14)(1.19)5.53
EBITDA margin-11.5%-20.4%-4.6%-14.2%-14.6%-32.4%-3.8%+18.2%
Depreciation1.871.691.150.991.651.920.721.98
Interest2.791.102.842.580.822.480.430.72
Profit before tax(8.23)(7.98)(4.37)(6.82)2.81(13.81)(2.11)3.47
Tax(0.15)(0.59)0.23(0.46)0.781.560.59(0.17)
Net profit(8.08)(7.39)(4.60)(6.36)2.03(15.37)(2.70)3.64
EPS (₹)(6.24)(5.83)(3.81)(7.23)1.89(12.78)(2.40)3.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue13112610893.4180.3562.0776.77
Revenue growth+4.4%+16.0%+15.9%+16.3%+29.5%-19.2%-
Other income14.211.820.303.121.140.110.02
Total expenses14913199.7390.8070.8361.2469.41
Employee cost0.0054.2734.3228.1222.3122.0024.63
EBITDA(17.75)(4.98)8.532.619.520.837.36
EBITDA margin-13.5%-4.0%+7.9%+2.8%+11.9%+1.3%+9.6%
Depreciation5.494.982.141.111.201.281.14
Interest7.344.096.045.196.676.411.70
Profit before tax(16.37)(12.23)0.65(0.57)2.79(6.75)4.54
Tax(0.04)1.721.22(0.13)0.41(1.89)0.48
Net profit(16.56)(13.95)(0.57)(2.98)1.69(4.86)3.90
Net profit margin-12.6%-11.1%-0.5%-3.2%+2.1%-7.8%+5.1%
EPS (₹)(13.53)(11.60)(0.47)(0.85)2.24(4.59)3.69
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-12.0312.0310.5610.5610.5610.56
Reserves & surplus-(2.54)6.62(4.98)(4.45)(7.15)(2.63)
Shareholders' funds (net worth)-9.4918.655.586.113.417.93
Minority interest-3.402.662.301.831.801.80
Secured loans-23.2228.5812.197.0010.6110.67
Unsecured loans-47.4447.4860.2562.9466.0853.49
Total debt-70.6676.0672.4469.9476.6964.16
Total liabilities-89.2310385.2382.6890.7582.81
Assets
Gross block-77.3866.5970.1467.2254.5653.94
Net block-46.8040.8246.4244.0332.7533.41
Capital work in progress-9.236.876.844.4614.0913.66
Investments-0.050.060.030.030.030.13
Inventories-12.9612.2712.4911.9711.0012.83
Sundry debtors-19.3017.4212.9613.3410.3310.71
Cash & bank balances-3.3922.813.202.8718.566.37
Loans & advances-5.123.715.428.963.763.06
Total current assets-40.7756.2134.0737.1443.6532.97
Total current liabilities-39.5330.2429.4927.6423.7318.86
Net working capital-1.2425.974.589.5019.9214.11
Total assets-89.2310385.2382.6890.7582.81
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-22.814.392.8718.566.374.55
Net cash from operating activities-4.83(0.96)9.86(0.50)7.434.99
Net cash from investing activities-(14.77)(0.45)(7.22)(1.91)(1.44)(4.03)
Net cash from financing activities-(9.48)19.83(2.32)(13.27)6.200.85
Net change in cash-(19.42)18.420.32(15.69)12.191.81
Closing cash-3.3922.813.202.8718.566.37
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+4.4%+16.0%+15.9%+16.3%+29.5%-19.2%-
EBITDA growth-256.4%-158.4%+226.8%-72.6%+1047.0%-88.7%-
PBT growth-33.9%-+9998.0%-+9998.0%-+46.0%
Net income growth-18.7%-2347.4%+80.9%-276.3%+134.8%-224.6%-
Revenue CAGR (3Y)+12.0%+16.1%+20.4%+6.8%+8.9%+1.8%+15.1%
EBITDA CAGR (3Y)--+117.4%-29.2%+22.3%-53.1%+0.5%
Profitability & leverage
Net income margin-12.5%-11.1%-0.5%-0.5%+3.0%-7.8%+5.3%
Return on capital employed-0.0%0.0%0.0%+9.3%0.0%+6.6%
Return on net worth-0.0%0.0%0.0%+13.3%0.0%+17.9%
Debt / equity-5.216.1312.1815.4012.4210.80
Long-term debt / equity-1.572.997.5010.059.788.77
Interest cover-31.58-41.0694.52346.0080.17-1,424.4427.33
Efficiency & per share
Fixed asset turnover-1.741.581.361.321.141.45
Inventory turnover-9.968.747.647.005.216.29
Debtors turnover-6.847.137.106.795.908.72
EPS (₹)(13.53)(11.60)(0.47)(0.85)2.24(4.59)3.69
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.007.8915.505.285.793.227.51
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue22.5324.5722.0721.2917.5719.3519.3518.60
Revenue growth (YoY)+28.2%+27.0%+14.1%+14.5%+14.1%---
Other income1.284.700.982.2610.004.370.130.39
Total expenses27.6235.0524.1326.3322.9930.3418.9919.15
EBITDA(5.09)(10.48)(2.06)(5.04)(5.42)(10.99)0.36(0.55)
EBITDA margin-22.6%-42.7%-9.3%-23.7%-30.8%-56.8%+1.9%-3.0%
Depreciation1.411.240.580.551.231.460.280.22
Interest2.811.971.982.540.772.810.380.33
Profit before tax(8.03)(8.99)(3.64)(5.87)2.58(10.89)(0.17)(0.71)
Tax(0.36)(1.07)(0.18)(0.47)0.510.98(0.08)(0.17)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue85.4877.9573.1463.3055.8043.2053.68
Revenue growth+9.7%+6.6%+15.6%+13.4%+29.2%-19.5%-
Other income17.935.173.010.060.300.170.16
Total expenses10890.5569.3455.5248.0842.9950.59
Employee cost0.0035.5220.2315.9812.1713.0616.03
EBITDA(23.02)(12.60)3.807.787.720.213.09
EBITDA margin-26.9%-16.2%+5.2%+12.3%+13.8%+0.5%+5.8%
Depreciation3.602.151.570.640.770.820.68
Interest7.273.925.404.816.036.141.37
Profit before tax(15.96)(13.50)(0.16)2.391.22(6.58)1.20
Tax(1.21)0.30(0.22)(0.52)0.35(1.63)0.34
Net profit(14.75)(13.80)0.060.480.87(4.95)0.86
Net profit margin-17.3%-17.7%+0.1%+0.8%+1.6%-11.5%+1.6%
EPS (₹)(12.21)(11.45)0.042.740.84(4.69)0.83
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital-12.0312.0310.5610.5610.5610.56
Reserves & surplus-13.0920.743.980.72(0.51)4.11
Shareholders' funds (net worth)-25.1232.7714.5411.2810.0514.67
Secured loans-13.3618.1014.0632.6310.5910.64
Unsecured loans-42.2045.4749.5728.7655.4347.16
Total debt-55.5663.5763.6361.3966.0257.80
Total liabilities-86.0310282.8077.2084.6181.04
Assets
Gross block-48.4342.7843.6040.8638.4428.43
Net block-31.4527.8030.3227.9626.4417.10
Capital work in progress-0.900.000.002.342.3411.55
Investments-9.239.2411.3711.3711.3711.47
Inventories-10.229.899.689.389.5011.46
Sundry debtors-23.1414.8012.0710.369.779.07
Cash & bank balances-0.3616.491.730.131.071.90
Loans & advances-36.553.612.503.527.454.94
Total current assets-70.2744.7925.9823.3927.7927.37
Total current liabilities-32.8614.6115.9014.5011.6211.65
Net working capital-37.4130.1810.088.8916.1715.72
Total assets-86.0310282.8077.2084.6181.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash-16.491.740.201.071.900.84
Net cash from operating activities-2.28(5.30)9.128.75(0.91)4.71
Net cash from investing activities-(6.48)(0.54)(5.32)0.83(2.10)(3.93)
Net cash from financing activities-(11.93)20.59(2.27)(10.52)2.180.29
Net change in cash-(16.13)14.751.52(0.94)(0.83)1.06
Closing cash-0.3616.491.730.131.071.90
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+9.7%+6.6%+15.6%+13.4%+29.2%-19.5%-
EBITDA growth-82.7%-431.6%-51.2%+0.8%+3576.2%-93.2%-
PBT growth-18.2%-8337.5%-+95.9%+9998.0%--31.0%
Net income growth-6.9%--87.5%-44.8%+117.6%-675.6%-
Revenue CAGR (3Y)+10.5%+11.8%+19.2%+5.7%+6.3%-0.4%+10.7%
EBITDA CAGR (3Y)--+162.5%+36.0%+37.0%-66.7%-13.5%
Profitability & leverage
Net income margin-17.3%-17.7%+0.1%+4.6%+1.6%-11.5%+1.6%
Return on capital employed-0.0%+5.0%+4.9%+8.4%0.0%+2.9%
Return on net worth-0.0%+0.1%+2.0%+5.4%0.0%+3.9%
Debt / equity-2.062.694.845.975.014.05
Long-term debt / equity-0.291.233.013.593.843.27
Interest cover-27.31-26.58242.1567.3786.76-1,006.5656.85
Efficiency & per share
Fixed asset turnover-1.711.691.501.411.291.93
Inventory turnover-7.757.476.645.914.124.83
Debtors turnover-4.115.445.645.544.596.00
EPS (₹)(12.21)(11.45)0.042.740.84(4.69)0.83
Dividend per share (₹)0.000.000.000.000.000.000.00
Book value per share (₹)0.0020.8827.2413.7710.689.5113.90

Competitors of Kerala Ayurveda

Kerala Ayurveda has 3 listed competitors in our database, 1 of them funded. They include AyurVAID Hospitals, AVN Arogya and Sreedhareeyam.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
AyurVAID Hospitals
ayurvaid.com2005Bengaluru, India$2.78M157
A chain of Ayurveda hospitals is operated in India.
AVN Arogya
avnarogya.in1930Madurai, India646
Offers Ayurvedic healthcare services for treatments and preventive medicine.
Sreedhareeyam
sreedhareeyam.com1999Ernakulam, India168
Offers Ayurvedic eye treatments, products, and clinics across India.
Premium access

Detailed competitors of Kerala Ayurveda

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Kerala Ayurveda

The website of Kerala Ayurveda (keralaayurveda.biz) receives about 32.1K visits a month and ranks #513,596 among all websites worldwide, #420 in Alternative and Natural Medicine.

  • Monthly visits
    32.1K

    ▼ 53.6% vs previous month

  • Unique visitors
    38.7K

    per month

  • Global rank
    #513,596

    among all websites

  • Category rank
    #420

    Health · Alternative and Natural Medicine

Similar websites

Websites whose visitors overlap most with Kerala Ayurveda. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
kairaliproducts.in
kairaliproducts.in
100%
#672,434–
ayurvedaacademy.com
ayurvedaacademy.com
97%
–
sitaramayurveda.com
sitaramayurveda.com
96%
–
theathreya.com
theathreya.com
92%
#2,028,204–
punarnava.net
punarnava.net
91%
#14,218,010–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Kerala Ayurveda

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Hospitals & Clinical Care

3 companies that operate in the same segment as Kerala Ayurveda (Hospitals & Clinical Care) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Cloudnine
Maternity, childcare, and fertility services are delivered via hospital chains.
2007Bengaluru, Karnataka, IndiaUSD 204.87 MUSD 140.46 M6,354
HCG
Chain of oncology hospitals
1989Bengaluru, Karnataka, IndiaUSD 36.59 MUSD 270.51 M321
Medanta
Chain of multi-super specialty healthcare hospitals
2004Gurugram, Haryana, IndiaUSD 104.7 MUSD 461.72 M12,240
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Kerala Ayurveda

Kerala Ayurveda reports consolidated net loss of Rs 7.98 crore in the June 2026 quarter | Capital Market News - Business Standard
Business Standard • 3 months ago
Kerala Ayurveda Ltd Approves Issuance Of 4000 Series 'A' NCDs Totaling 400 Million Rupees
Reuters • 7 months ago
Kerala Ayurveda Received Settlement Order From SEBI
Reuters • 9 months ago
Kerala Ayurveda consolidated net profit rises 521.88% in the June 2025 quarter | Capital Market News - Business Standard
Business Standard • 1 year ago
Authum Investment picks up 61% stake in Katra Phytochem, 15% in Kerala Ayurveda - CNBC TV18
CNBCTV18 • 1 year ago
Kerala Ayurveda reports consolidated net loss of Rs 15.54 crore in the March 2025 quarter | Capital Market News - Business Standard
Business Standard • 1 year ago
Porinju Veliyath’s largest holdings every investor must know about - Stock Insights News | The Financial Express
Financial Express • 1 year ago
Kerala Ayurveda Ltd reports Q3 net loss of Rs 3 crore
Fashionnetwork • 1 year ago
Kerala Ayurveda reports consolidated net profit of Rs 1.03 crore in the September 2022 quarter
India Infoline • 1 year ago
Kerala Ayurveda to hold board meeting
India Infoline • 1 year ago
Premium access

Complete news archive for Kerala Ayurveda

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Kerala Ayurveda

Kerala Ayurveda was founded in 1945.

Kerala Ayurveda is headquartered in Kochi, India. It is registered at Kochi, Kerala, India.

Kerala Ayurveda has 367 employees.

The primary company behind Kerala Ayurveda, Kerala Ayurveda Limited, reported revenue of ₹145 Cr for FY 2026, up 4% year on year.

Kerala Ayurveda, established in 1945, excels in providing healthcare solutions, hospital chains, complementary and alternative therapy hospitals, and ayurveda. Chain of complementary and alternative therapy hospitals. Committed to advancing standards, it focuses on innovation, efficiency, and delivering value to clients worldwide.

Kerala Ayurveda's top competitors include AyurVAID Hospitals, Sreedhareeyam and AVN Arogya.

Kerala Ayurveda offers Myaxyl Oil, Triphala Tablets, Neelibringadi Keram, and Brahmi Pearls Capsules.

Yes, Kerala Ayurveda is publicly traded on BSE under the ticker symbol KERALAYUR.

Kerala Ayurveda operates through Kerala Ayurveda Limited.

The legal entities of Kerala Ayurveda currently have 11 directors, including Shilpa Kiran Gududur, Rajesh Sharma, Kunjupanicker Anilkumar and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available